RECRUITING

Pharmacogenomics of Asparaginase Induced Hepatotoxicity

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.

Official Title

Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Quick Facts

Study Start:2018-05-22
Study Completion:2026-05-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03568266

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL
  2. * Receiving asparaginase as part of the primary treatment regimen
  3. * Ability to understand and the willingness to sign a written informed consent
  4. * For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)
  1. * Patients who are unable to give informed consent

Contacts and Locations

Study Contact

Christine Duran
CONTACT
323-865-0371
Duran_C@med.usc.edu

Principal Investigator

Houda Alachkar, Ph.D.
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
United States

Collaborators and Investigators

Sponsor: University of Southern California

  • Houda Alachkar, Ph.D., PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-05-22
Study Completion Date2026-05-22

Study Record Updates

Study Start Date2018-05-22
Study Completion Date2026-05-22

Terms related to this study

Additional Relevant MeSH Terms

  • Acute Lymphoblastic Leukemia